Frequently Asked Questions
The market is segmented based on Global Congenital Heart Disease Market By Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Others), Diagnosis (Electrocardiogram, Chest X-ray, Echocardiogram, Transoesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac CT Scan or MRI, Cardiac Catheterization, Other), Treatment (Medications, Surgery, Watchful Waiting, Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Congenital Heart Diseases Market size was valued at USD 4110.00 USD Million in 2022.
The Global Congenital Heart Diseases Market is projected to grow at a CAGR of 9.1% during the forecast period of 2023 to 2030.
The major players operating in the market include Abbott Laboratories, AstraZeneca, Becton Dickson & Co., BioRad Laboratories, Boston Scientific Corp., Laboratory Corporation of America Holdings , F. Hoffmann La Roche , Glaxosmithkline, Janssen Pharmaceuticals, Medtronic, Viatris , Novartis, Pfizer , Randox Laboratories , Response Biomedical Corporation, Sanofi, Siemens Healthineers, Thermo Fisher Scientific , Vericel Corporation.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
